A phase 2 trial in colorectal cancer, run by AC Camargo Cancer Center, now recruiting.
Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer is a phase 2, interventional study registered as NCT06793137 by AC Camargo Cancer Center, with a registry enrolment figure of 100 participants, started 2024-07-22 and due to reach its primary completion in 2025-10-31. Interventions recorded: Metronidazole. Conditions listed: Rectal Cancer, Adenocarcinoma. Primary outcome: Complete clinical response in total neoadjuvant treatment of rectal adenocarcinoma. Colorectal eligibility wording from the registry: "* Patients over 18 years old with middle and lower rectal adenocarcinoma, classified as locally advanced or where the tumor´s location necessitates rectal amputation surgery;". Sites: Brazil. No results are recorded here; the registry entry is the source.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.